Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Oct 10;50(19):10839–10856. doi: 10.1093/nar/gkac864

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Published by Oxford University Press on behalf of Nucleic Acids Research 2022.

This work is written by (a) US Government employee(s) and is in the public domain in the US.

PMC Copyright notice

Figure 3. — Thyclotide 5 is successfully taken up by cells and does not colocalize with endosomes 16 hours after treatment. (A) FACS of SKHEP1 cells either non-treated (blue) or treated with 5 μM of either FAM-aegPNA 4 (orange) or FAM-thyclotide 5 (red). Positive cells were determined by having a fluorescence higher than the non-treated cells. MFI refers to the mean fluorescence intensity. (B) FACS of HepG2 cells either non-treated (blue) or treated with 5 μM of FAM-aegPNA 4 (orange) or FAM-thyclotide 5 (red). Positive cells were determined by having a fluorescence higher than the non-treated cells. MFI refers to the mean fluorescence intensity. (C) 3D volume reconstruction of 0.15 μm z-steps super-resolution microscopy imaging of SKHEP1 cells treated with FAM-thyclotide 5. Cells were stained with Membrite Fix 640/660 cell membrane marker (white), CellLight BacMam 2.0 early endosomes-RFP marker (orange) and Hoechst 33342 nucleus staining solution (blue). The membrane marker channel was removed from the right picture for a better visualization of the cytoplasmic diffusion of FAM-thyclotide 5 (green).